{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:07:52Z","timestamp":1794834472928,"version":"4.9.1"},"publisher-location":"Cham","reference-count":200,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032177742","type":"print"},{"value":"9783032177759","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-17775-9_1","type":"book-chapter","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T12:13:20Z","timestamp":1771157600000},"page":"1-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune Responses to Human Papillomavirus After Infection and Vaccination"],"prefix":"10.1007","author":[{"given":"Hannah S.","family":"Newton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Zwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy J.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/jgo.18.00233","volume":"5","author":"AE Atkinson","year":"2019","unstructured":"Atkinson AE, Mandujano CAM, Bejarano S, Kennedy LS, Tsongalis GJ (2019) Screening for human papillomavirus in a low- and middle-income country. J Glob Oncol 5:Jgo1800233. https:\/\/doi.org\/10.1200\/jgo.18.00233","journal-title":"J Glob Oncol"},{"issue":"3","key":"1_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.6026\/97320630013086","volume":"13","author":"S Baidya","year":"2017","unstructured":"Baidya S, Das R, Kabir MG, Arifuzzaman M (2017) Epitope design of L1 protein for vaccine production against Human papilloma virus types 16 and 18. Bioinformation 13(3):86\u201393. https:\/\/doi.org\/10.6026\/97320630013086","journal-title":"Bioinformation"},{"issue":"5","key":"1_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100056","volume":"1","author":"RV Barnabas","year":"2022","unstructured":"Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, Galloway DA, Pinder LF, Donnell D, Wakhungu I, Congo O, Biwott C, Kimanthi S, Oluoch L, Heller KB, Leingang H, Morrison S, Rechkina E, Cherne S, Schaafsma TT, McClelland RS, Celum C, Baeten JM, Mugo N (2022) Efficacy of single-dose HPV vaccination among young African women. NEJM Evid 1(5):EVIDoa2100056. https:\/\/doi.org\/10.1056\/EVIDoa2100056","journal-title":"NEJM Evid"},{"issue":"12","key":"1_CR4","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","volume":"29","author":"RV Barnabas","year":"2023","unstructured":"Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, Galloway DA, Pinder LF, Donnell D, Wakhungu IN, Biwott C, Kimanthi S, Heller KB, Kanjilal DG, Pacella D, Morrison S, Rechkina EA, Cherne SL, Schaafsma TT, McClelland RS, Celum C, Baeten JM, Mugo NR (2023) Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nat Med 29(12):3224\u20133232. https:\/\/doi.org\/10.1038\/s41591-023-02658-0","journal-title":"Nat Med"},{"key":"1_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7693183","volume":"2019","author":"J Barrios De Tomasi","year":"2019","unstructured":"Barrios De Tomasi J, Opata MM, Mowa CN (2019) Immunity in the cervix: interphase between immune and cervical epithelial cells. J Immunol Res 2019:7693183. https:\/\/doi.org\/10.1155\/2019\/7693183","journal-title":"J Immunol Res"},{"issue":"41","key":"1_CR6","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.vaccine.2014.07.014","volume":"32","author":"L Barzon","year":"2014","unstructured":"Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Pascucci MG, Lazzarotto T, Caputo A, Pal\u00f9 G (2014) Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Vaccine 32(41):5357\u20135362. https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.014","journal-title":"Vaccine"},{"issue":"11","key":"1_CR7","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/s1470-2045(21)00453-8","volume":"22","author":"P Basu","year":"2021","unstructured":"Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, Verma Y, Esmy PO, Poli URR, Shah A, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Divate U, Vashist S, Mishra G, Jadhav R, Siddiqi M, Sankaran S, Prabhu PR, Kannan T, Varghese R, Shastri SS, Anantharaman D, Gheit T, Tommasino M, Sauvaget C, Pillai MR, Sankaranarayanan R (2021) Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol 22(11):1518\u20131529. https:\/\/doi.org\/10.1016\/s1470-2045(21)00453-8","journal-title":"Lancet Oncol"},{"issue":"1","key":"1_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37377-0","volume":"14","author":"MC Bedard","year":"2023","unstructured":"Bedard MC, Chihanga T, Carlile A, Jackson R, Brusadelli MG, Lee D, VonHandorf A, Rochman M, Dexheimer PJ, Chalmers J, Nuovo G, Lehn M, Williams DEJ, Kulkarni A, Carey M, Jackson A, Billingsley C, Tang A, Zender C, Patil Y, Wise-Draper TM, Herzog TJ, Ferris RL, Kendler A, Aronow BJ, Kofron M, Rothenberg ME, Weirauch MT, Van Doorslaer K, Wikenheiser-Brokamp KA, Lambert PF, Adam M, Steven Potter S, Wells SI (2023) Single cell transcriptomic analysis of HPV16-infected epithelium identifies a keratinocyte subpopulation implicated in cancer. Nat Commun 14(1):1975. https:\/\/doi.org\/10.1038\/s41467-023-37377-0","journal-title":"Nat Commun"},{"issue":"10","key":"1_CR9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.vaccine.2014.01.008","volume":"32","author":"SL Bissett","year":"2014","unstructured":"Bissett SL, Draper E, Myers RE, Godi A, Beddows S (2014) Cross-neutralizing antibodies elicited by the Cervarix\u00ae human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine 32(10):1139\u20131146. https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.008","journal-title":"Vaccine"},{"issue":"3","key":"1_CR10","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1093\/cid\/ciaa1897","volume":"73","author":"L Boey","year":"2021","unstructured":"Boey L, Curinckx A, Roelants M, Derdelinckx I, Van Wijngaerden E, De Munter P, Vos R, Kuypers D, Van Cleemput J, Vandermeulen C (2021) Immunogenicity and safety of the 9-Valent Human Papillomavirus Vaccine in solid organ transplant recipients and adults infected with Human immunodeficiency virus (HIV). Clin Infect Dis 73(3):e661\u2013e671. https:\/\/doi.org\/10.1093\/cid\/ciaa1897","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.immuni.2011.01.015","volume":"34","author":"M Bomsel","year":"2011","unstructured":"Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, Mouz N, Amacker M, Chalifour A, Diomede L, Devillier G, Cong Z, Wei Q, Gao H, Qin C, Yang GB, Zurbriggen R, Lopalco L, Fleury S (2011) Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34(2):269\u2013280. https:\/\/doi.org\/10.1016\/j.immuni.2011.01.015","journal-title":"Immunity"},{"key":"1_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2022.200236","volume":"13","author":"DR Brown","year":"2022","unstructured":"Brown DR, Castellsagu\u00e9 X, Ferris D, Garland SM, Huh W, Steben M, Wheeler CM, Saah A, Luxembourg A, Li S, Velicer C (2022) Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women. Tumour Virus Res 13:200236. https:\/\/doi.org\/10.1016\/j.tvr.2022.200236","journal-title":"Tumour Virus Res"},{"issue":"1","key":"1_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/cmr.16.1.1-17.2003","volume":"16","author":"EM Burd","year":"2003","unstructured":"Burd EM (2003) Human papillomavirus and cervical cancer. Clin Microbiol Rev 16(1):1\u201317. https:\/\/doi.org\/10.1128\/cmr.16.1.1-17.2003","journal-title":"Clin Microbiol Rev"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.virol.2014.12.028","volume":"476","author":"D Bzhalava","year":"2015","unstructured":"Bzhalava D, Eklund C, Dillner J (2015) International standardization and classification of human papillomavirus types. Virology 476:341\u2013344. https:\/\/doi.org\/10.1016\/j.virol.2014.12.028","journal-title":"Virology"},{"key":"1_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126817","volume":"50","author":"JJ Carter","year":"2025","unstructured":"Carter JJ, Smith RA, Scherer EM, Skibinski DAG, Sankaranarayanan S, Luxembourg A, Kollmann T, Marty KD, Sadarangani M, Dobson S, Galloway DA (2025) Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine. Vaccine 50:126817. https:\/\/doi.org\/10.1016\/j.vaccine.2025.126817","journal-title":"Vaccine"},{"issue":"4","key":"1_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/infdis\/jiu139","volume":"210","author":"X Castellsagu\u00e9","year":"2014","unstructured":"Castellsagu\u00e9 X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmer\u00f3n J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L (2014) Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16\/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis 210(4):517\u2013534. https:\/\/doi.org\/10.1093\/infdis\/jiu139","journal-title":"J Infect Dis"},{"key":"1_CR17","volume-title":"HPV vaccine administration","author":"CDC","year":"2021","unstructured":"CDC (2021) HPV vaccine administration. CDC. https:\/\/www.cdc.gov\/vaccines\/vpd\/hpv\/hcp\/administration.html. Accessed 19 June 2025"},{"key":"1_CR18","volume-title":"Human papillomavirus (HPV) vaccine safety","author":"CDC","year":"2025","unstructured":"CDC (2025) Human papillomavirus (HPV) vaccine safety. Available from: https:\/\/www.cdc.gov\/vaccine-safety\/vaccines\/hpv.html"},{"key":"1_CR19","unstructured":"Cecolin (2021) Recombinant human papillomavirus bivalent (types 16, 18) vaccine (Escherichia coli) [package insert]. Xiamen Innovax Biotech Co., Ltd., Fujian Province, China"},{"key":"1_CR20","unstructured":"Cervarix (2014) Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant [package insert]. GlaxoSmithKline Biologicals, Rizensart, Belgium"},{"key":"1_CR21","unstructured":"Cervavac (2022) Quadrivalent human papillomavirus (serotype 6, 11, 16, & 18) vaccine recombinant [package insert]. Serum Institute of India Pvt. Ltd., Hadapsar, Pune-411028, India"},{"key":"1_CR22","volume-title":"CERVAVAC\u00ae vaccine information","author":"Cervavac","year":"2023","unstructured":"Cervavac (2023) CERVAVAC\u00ae vaccine information. Available from: https:\/\/cervavac.com\/vaccine\/"},{"key":"1_CR23","doi-asserted-by":"publisher","unstructured":"Cheng L, Wang Y, Du J (2020) Human papillomavirus vaccines: an updated review. Vaccines (Basel) 8(3). https:\/\/doi.org\/10.3390\/vaccines8030391","DOI":"10.3390\/vaccines8030391"},{"issue":"6","key":"1_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11061609","volume":"11","author":"L Chihu-Amparan","year":"2023","unstructured":"Chihu-Amparan L, Pedroza-Saavedra A, Gutierrez-Xicotencatl L (2023) The immune response generated against HPV infection in men and its implications in the diagnosis of cancer. Microorganisms 11(6):1609. https:\/\/doi.org\/10.3390\/microorganisms11061609","journal-title":"Microorganisms"},{"key":"1_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100731","volume":"34","author":"K Chu","year":"2023","unstructured":"Chu K, Bi ZF, Huang WJ, Li YF, Zhang L, Yang CL, Jiang HM, Zang X, Chen Q, Liu DL, Pan HX, Huang Y, Zheng FZ, Zhang QF, Sun G, Su YY, Huang SJ, Pan HR, Wu T, Hu YM, Zhang J, Zhu FC, Xia NS (2023) Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6\/11\/16\/18\/31\/33\/45\/52\/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial. Lancet Reg Health West Pac 34:100731. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100731","journal-title":"Lancet Reg Health West Pac"},{"key":"1_CR26","doi-asserted-by":"publisher","DOI":"10.1533\/9781908818171","volume-title":"Human papillomavirus infections: from the laboratory to clinical practice","author":"F Cobo","year":"2012","unstructured":"Cobo F (2012) Human papillomavirus infections: from the laboratory to clinical practice. Elsevier"},{"issue":"13","key":"1_CR27","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1128\/jvi.76.13.6480-6486.2002","volume":"76","author":"A-L Combita","year":"2002","unstructured":"Combita A-L, Touz\u00e9 A, Bousarghin L, Christensen ND, Coursaget P (2002) Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76(13):6480\u20136486. https:\/\/doi.org\/10.1128\/jvi.76.13.6480-6486.2002","journal-title":"J Virol"},{"key":"1_CR28","volume-title":"Regulatory approval for Innovax\u2019s HPV vaccine, Cecolin\u00ae9 from NMPA","author":"DCVMN International","year":"2025","unstructured":"DCVMN International (2025) Regulatory approval for Innovax\u2019s HPV vaccine, Cecolin\u00ae9 from NMPA. Available from: https:\/\/dcvmn.org\/regulatory-approval-for-innovaxs-hpv-vaccine-cecolin9-from-nmpa\/"},{"issue":"2","key":"1_CR29","first-page":"472","volume":"62","author":"A de Jong","year":"2002","unstructured":"de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R (2002) Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62(2):472\u2013479","journal-title":"Cancer Res"},{"issue":"2","key":"1_CR30","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/s2214-109x(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM (2020) Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 8(2):e180\u2013e190. https:\/\/doi.org\/10.1016\/s2214-109x(19)30488-7","journal-title":"Lancet Glob Health"},{"issue":"3","key":"1_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ygyno.2013.05.033","volume":"130","author":"R De Vincenzo","year":"2013","unstructured":"De Vincenzo R, Ricci C, Conte C, Scambia G (2013) HPV vaccine cross-protection: highlights on additional clinical benefit. Gynecol Oncol 130(3):642\u2013651. https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.033","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1_CR32","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/ijc.24116","volume":"124","author":"H De Vuyst","year":"2009","unstructured":"De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124(7):1626\u20131636. https:\/\/doi.org\/10.1002\/ijc.24116","journal-title":"Int J Cancer"},{"issue":"6","key":"1_CR33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/jnci\/djaa128","volume":"113","author":"AA Deshmukh","year":"2021","unstructured":"Deshmukh AA, Suk R, Shiels MS, Damgacioglu H, Lin YY, Stier EA, Nyitray AG, Chiao EY, Nemutlu GS, Chhatwal J, Schmeler K, Sigel K, Sonawane K (2021) Incidence trends and burden of human papillomavirus-associated cancers among women in the United States, 2001-2017. J Natl Cancer Inst 113(6):792\u2013796. https:\/\/doi.org\/10.1093\/jnci\/djaa128","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4161\/hv.4.6.6912","volume":"4","author":"FJ Dessy","year":"2008","unstructured":"Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA (2008) Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16\/18 cervical cancer vaccine. Hum Vaccin 4(6):425\u2013434. https:\/\/doi.org\/10.4161\/hv.4.6.6912","journal-title":"Hum Vaccin"},{"issue":"Suppl 5","key":"1_CR35","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","volume":"30","author":"J Doorbar","year":"2012","unstructured":"Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA (2012) The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55\u2013F70. https:\/\/doi.org\/10.1016\/j.vaccine.2012.06.083","journal-title":"Vaccine"},{"issue":"47","key":"1_CR36","doi-asserted-by":"publisher","first-page":"8585","DOI":"10.1016\/j.vaccine.2011.09.021","volume":"29","author":"E Draper","year":"2011","unstructured":"Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, Soldan K, Beddows S (2011) Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 29(47):8585\u20138590. https:\/\/doi.org\/10.1016\/j.vaccine.2011.09.021","journal-title":"Vaccine"},{"issue":"5","key":"1_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061825","volume":"8","author":"E Draper","year":"2013","unstructured":"Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S (2013) A randomized, observer-blinded immunogenicity trial of Cervarix(\u00ae) and Gardasil(\u00ae) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One 8(5):e61825. https:\/\/doi.org\/10.1371\/journal.pone.0061825","journal-title":"PLoS One"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3389\/fimmu.2020.01141","volume":"11","author":"M Duchemin","year":"2020","unstructured":"Duchemin M, Tudor D, Cottignies-Calamarte A, Bomsel M (2020) Antibody-dependent cellular phagocytosis of HIV-1-infected cells is efficiently triggered by IgA targeting HIV-1 envelope subunit gp41. Front Immunol 11:1141. https:\/\/doi.org\/10.3389\/fimmu.2020.01141","journal-title":"Front Immunol"},{"issue":"10","key":"1_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4161\/hv.5.10.9518","volume":"5","author":"MH Einstein","year":"2009","unstructured":"Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G (2009a) Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 5(10):705\u2013719. https:\/\/doi.org\/10.4161\/hv.5.10.9518","journal-title":"Hum Vaccin"},{"issue":"6","key":"1_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1473-3099(09)70108-2","volume":"9","author":"MH Einstein","year":"2009","unstructured":"Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D (2009b) Clinician\u2019s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 9(6):347\u2013356. https:\/\/doi.org\/10.1016\/S1473-3099(09)70108-2","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"1_CR41","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4161\/hv.7.12.18282","volume":"7","author":"MH Einstein","year":"2011","unstructured":"Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, Moris P, Giannini SL, Schuind A, Datta SK, Descamps D (2011a) Comparison of the immunogenicity of the human papillomavirus (HPV)-16\/18 vaccine and the HPV-6\/11\/16\/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 7(12):1359\u20131373. https:\/\/doi.org\/10.4161\/hv.7.12.18282","journal-title":"Hum Vaccin"},{"issue":"12","key":"1_CR42","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","volume":"7","author":"MH Einstein","year":"2011","unstructured":"Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G (2011b) Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 7(12):1343\u20131358. https:\/\/doi.org\/10.4161\/hv.7.12.18281","journal-title":"Hum Vaccin"},{"issue":"2","key":"1_CR43","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2239085","volume":"19","author":"MK Ellingson","year":"2023","unstructured":"Ellingson MK, Sheikha H, Nyhan K, Oliveira CR, Niccolai LM (2023) Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review. Hum Vaccin Immunother 19(2):2239085. https:\/\/doi.org\/10.1080\/21645515.2023.2239085","journal-title":"Hum Vaccin Immunother"},{"key":"1_CR201","doi-asserted-by":"publisher","unstructured":"Falcaro M, Soldan K, Ndlela B, Sasieni P (2024) Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study. BMJ (Clinical research ed.), 385:e077341. https:\/\/doi.org\/10.1136\/bmj-2023-077341","DOI":"10.1136\/bmj-2023-077341"},{"key":"1_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101350","volume":"52","author":"R Farrell","year":"2024","unstructured":"Farrell R, Zaunders J, Poynten IM, Anderson L, Evans L (2024) Concurrent nonavalent human papillomavirus (HPV) vaccination and immune stimulation with imiquimod to treat recalcitrant HPV-associated high grade vaginal intra-epithelial neoplasia. Gynecol Oncol Rep 52:101350. https:\/\/doi.org\/10.1016\/j.gore.2024.101350","journal-title":"Gynecol Oncol Rep"},{"key":"1_CR45","volume-title":"Human papillomavirus vaccine","author":"FDA","year":"2024","unstructured":"FDA (2024) Human papillomavirus vaccine. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/human-papillomavirus-vaccine"},{"issue":"11","key":"1_CR46","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/infdis\/jiy743","volume":"219","author":"N Folschweiller","year":"2019","unstructured":"Folschweiller N, Behre U, Dionne M, Durando P, Esposito S, Ferguson L, Ferguson M, Hillemanns P, McNeil SA, Peters K, Ramjattan B, Schwarz TF, Supparatpinyo K, Suryakirian PV, Janssens M, Moris P, Decreux A, Poncelet S, Struyf F (2019) Long-term cross-reactivity against nonvaccine human papillomavirus types 31 and 45 after 2- or 3-dose schedules of the AS04-adjuvanted human HPV-16\/18 vaccine. J Infect Dis 219(11):1799\u20131803. https:\/\/doi.org\/10.1093\/infdis\/jiy743","journal-title":"J Infect Dis"},{"issue":"19","key":"1_CR47","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"Future_II_Study_Group","year":"2007","unstructured":"Future_II_Study_Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915\u20131927","journal-title":"N Engl J Med"},{"key":"1_CR48","unstructured":"GARDASIL\u00ae (2015) Human papillomavirus quadrivalent (types 6, 11, 16, and 18 vaccine, recombinant) [package insert]. Merck & Co., Inc., Whitehouse Station, NJ"},{"key":"1_CR49","unstructured":"GARDASIL\u00ae (2024) GARDASIL\u00ae9 [package insert]. Merck Sharp & Dohme LLC, Rahway, NJ"},{"issue":"3","key":"1_CR50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1089\/vim.2016.0142","volume":"30","author":"N Ghorban Hosseini","year":"2017","unstructured":"Ghorban Hosseini N, Tebianian M, Farhadi A, Hossein Khani A, Rahimi A, Mortazavi M, Hosseini SY, Taghizadeh M, Rezaei M, Mahdavi M (2017) In silico analysis of L1\/L2 sequences of Human papillomaviruses: implication for universal Vaccine design. Viral Immunol 30(3):210\u2013223. https:\/\/doi.org\/10.1089\/vim.2016.0142","journal-title":"Viral Immunol"},{"issue":"29","key":"1_CR51","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1200\/jco.2015.61.6995","volume":"33","author":"ML Gillison","year":"2015","unstructured":"Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C (2015) Epidemiology of Human Papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 33(29):3235\u20133242. https:\/\/doi.org\/10.1200\/jco.2015.61.6995","journal-title":"J Clin Oncol"},{"issue":"8","key":"1_CR52","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1086\/521679","volume":"196","author":"AR Giuliano","year":"2007","unstructured":"Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E (2007) Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 196(8):1153\u20131162. https:\/\/doi.org\/10.1086\/521679","journal-title":"J Infect Dis"},{"issue":"9769","key":"1_CR53","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/s0140-6736(10)62342-2","volume":"377","author":"AR Giuliano","year":"2011","unstructured":"Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D (2011) Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 377(9769):932\u2013940. https:\/\/doi.org\/10.1016\/s0140-6736(10)62342-2","journal-title":"Lancet"},{"issue":"12","key":"1_CR54","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1002\/ijc.29082","volume":"136","author":"AR Giuliano","year":"2015","unstructured":"Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, Monsonego J, Franceschi S (2015a) EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer 136(12):2752\u20132760. https:\/\/doi.org\/10.1002\/ijc.29082","journal-title":"Int J Cancer"},{"key":"1_CR55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pvr.2015.06.007","volume":"1","author":"AR Giuliano","year":"2015","unstructured":"Giuliano AR, Viscidi R, Torres BN, Ingles DJ, Sudenga SL, Villa LL, Baggio ML, Abrahamsen M, Quiterio M, Salmeron J, Lazcano-Ponce E (2015b) Seroconversion following anal and genital HPV infection in men: the HIM study. Papillomavirus Res 1:109\u2013115. https:\/\/doi.org\/10.1016\/j.pvr.2015.06.007","journal-title":"Papillomavirus Res"},{"issue":"9","key":"1_CR56","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1001\/jamaoto.2023.1573","volume":"149","author":"AR Giuliano","year":"2023","unstructured":"Giuliano AR, Felsher M, Waterboer T, Mirghani H, Mehanna H, Roberts C, Chen YT, Lynam M, Pedr\u00f3s M, Sanchez E, Sirak B, Surati S, Alemany L, Morais E, Pav\u00f3n MA (2023) Oral human papillomavirus prevalence and genotyping among a healthy adult population in the US. JAMA Otolaryngol Head Neck Surg 149(9):783\u2013795. https:\/\/doi.org\/10.1001\/jamaoto.2023.1573","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"1_CR57","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/infdis\/jiad485","volume":"229","author":"AR Giuliano","year":"2024","unstructured":"Giuliano AR, Palefsky JM, Goldstone SE, Dubin B, Saah A, Luxembourg A, Velicer C, Tota JE (2024) High risk of new HPV infection acquisition among unvaccinated young men. J Infect Dis 229(3):707\u2013718. https:\/\/doi.org\/10.1093\/infdis\/jiad485","journal-title":"J Infect Dis"},{"issue":"1","key":"1_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2425146","volume":"21","author":"AR Giuliano","year":"2025","unstructured":"Giuliano AR, Palefsky JM, Goldstone SE, Bornstein J, De Coster I, Guevara AM, Mogensen O, Schilling A, Van Damme P, Vandermeulen C, Ellison MC, Kaplan S, Lin J, Bonawitz R, Luxembourg A (2025) Immunogenicity of the 9-valent human papillomavirus vaccine: post hoc analysis from five phase 3 studies. Hum Vaccin Immunother 21(1):2425146. https:\/\/doi.org\/10.1080\/21645515.2024.2425146","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"1_CR59","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00779-22","volume":"10","author":"A Godi","year":"2022","unstructured":"Godi A, Vaghadia S, Cocuzza C, Miller E, Beddows S (2022) Contribution of surface-exposed loops on the HPV16 capsid to antigenic domains recognized by vaccine or natural infection induced neutralizing antibodies. Microbiol Spectr 10(3):e0077922. https:\/\/doi.org\/10.1128\/spectrum.00779-22","journal-title":"Microbiol Spectr"},{"issue":"1","key":"1_CR60","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41541-024-00941-w","volume":"9","author":"P Gray","year":"2024","unstructured":"Gray P, Mariz FC, Eklund C, Eriksson T, Faust H, Kann H, M\u00fcller M, Paavonen J, Pimenoff VN, Sehr P, Surcel HM, Dillner J, Waterboer T, Lehtinen M (2024) Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study. NPJ Vaccines 9(1):146. https:\/\/doi.org\/10.1038\/s41541-024-00941-w","journal-title":"NPJ Vaccines"},{"issue":"4","key":"1_CR61","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/bjc.2015.462","volume":"114","author":"A Handisurya","year":"2016","unstructured":"Handisurya A, Schellenbacher C, Haitel A, Senger T, Kirnbauer R (2016) Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Br J Cancer 114(4):409\u2013416. https:\/\/doi.org\/10.1038\/bjc.2015.462","journal-title":"Br J Cancer"},{"issue":"1","key":"1_CR62","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12916-018-1098-3","volume":"16","author":"T Harder","year":"2018","unstructured":"Harder T, Wichmann O, Klug SJ, van der Sande MAB, Wiese-Posselt M (2018) Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med 16(1):110. https:\/\/doi.org\/10.1186\/s12916-018-1098-3","journal-title":"BMC Med"},{"issue":"4","key":"1_CR63","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","volume":"93","author":"CD Harro","year":"2001","unstructured":"Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93(4):284\u2013292. https:\/\/doi.org\/10.1093\/jnci\/93.4.284","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2253598","volume":"19","author":"H Hempel","year":"2023","unstructured":"Hempel H, Mantis N, Heaney CD, Pinto LA (2023) The SeroNet clinical and translational serology task force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop. Hum Vaccin Immunother 19(2):2253598. https:\/\/doi.org\/10.1080\/21645515.2023.2253598","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"1_CR65","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.4161\/hv.34408","volume":"10","author":"DM Herrin","year":"2014","unstructured":"Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE (2014) Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. Hum Vaccin Immunother 10(12):3446\u20133454. https:\/\/doi.org\/10.4161\/hv.34408","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1_CR66","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1908059","volume":"18","author":"J Hoes","year":"2022","unstructured":"Hoes J, Pasmans H, Schurink-van\u2019t Klooster TM, van der Klis FRM, Donken R, Berkhof J, de Melker HE (2022) Review of long-term immunogenicity following HPV vaccination: gaps in current knowledge. Hum Vaccin Immunother 18(1):1908059. https:\/\/doi.org\/10.1080\/21645515.2021.1908059","journal-title":"Hum Vaccin Immunother"},{"key":"1_CR67","volume-title":"HPV serology laboratory","author":"HPV Serology Laboratory","year":"2025","unstructured":"HPV Serology Laboratory (2025) HPV serology laboratory. Frederick National Laboratory. https:\/\/frederick.cancer.gov\/research\/vaccine-immunity-and-cancer-directorate\/serology-laboratory\/hpv-operating-procedures. Accessed 17 June 2025"},{"key":"1_CR68","volume-title":"StatPearls","author":"Z Jamal","year":"2025","unstructured":"Jamal Z, Anjum F (2025) Oropharyngeal squamous cell carcinoma. In: StatPearls. StatPearls publishing copyright \u00a9 2025, StatPearls Publishing LLC, Treasure Island"},{"issue":"1","key":"1_CR69","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","volume":"41","author":"S Joshi","year":"2023","unstructured":"Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, Rani Reddy Poli U, Malvi SG, Esmy PO, Lucas E, Verma Y, Shah A, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Divate U, Vashist S, Mishra G, Jadhav R, Siddiqi M, Sankaran S, Pillai Rameshwari Ammal Kannan T, Kartha P, Shastri SS, Sauvaget C, Radhakrishna Pillai M, Waterboer T, M\u00fcller M, Sehr P, Unger ER, Sankaranarayanan R, Basu P (2023) Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine 41(1):236\u2013245. https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.044","journal-title":"Vaccine"},{"issue":"12","key":"1_CR70","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/s1473-3099(17)30468-1","volume":"17","author":"K Kavanagh","year":"2017","unstructured":"Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, Bhatia R, Moore C, Cubie H, Cruickshank M, Robertson C (2017) Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 17(12):1293\u20131302. https:\/\/doi.org\/10.1016\/s1473-3099(17)30468-1","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"1_CR71","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s12033-021-00374-z","volume":"63","author":"M Kayyal","year":"2021","unstructured":"Kayyal M, Bolhassani A, Noormohammadi Z, Sadeghizadeh M (2021) In silico design and immunological studies of two novel multiepitope DNA-based vaccine candidates against high-risk human papillomaviruses. Mol Biotechnol 63(12):1192\u20131222. https:\/\/doi.org\/10.1007\/s12033-021-00374-z","journal-title":"Mol Biotechnol"},{"issue":"11","key":"1_CR72","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.vaccine.2011.01.001","volume":"29","author":"TJ Kemp","year":"2011","unstructured":"Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA (2011) HPV16\/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29(11):2011\u20132014. https:\/\/doi.org\/10.1016\/j.vaccine.2011.01.001","journal-title":"Vaccine"},{"issue":"1","key":"1_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41541-024-00949-2","volume":"9","author":"TJ Kemp","year":"2024","unstructured":"Kemp TJ, Panicker G, Eklund C, Nie J, Wang Y, Beddows S, Rigsby P, Huang W, Dillner J, Unger ER, Pinto LA, Wilkinson DE (2024) WHO international standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58. NPJ Vaccines 9(1):165. https:\/\/doi.org\/10.1038\/s41541-024-00949-2","journal-title":"NPJ Vaccines"},{"key":"1_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100401","volume":"23","author":"SK Kjaer","year":"2020","unstructured":"Kjaer SK, Nyg\u00e5rd M, Sundstr\u00f6m K, Dillner J, Tryggvadottir L, Munk C, Berger S, Enerly E, Hortlund M, \u00c1g\u00fastsson \u00c1I, Bjelkenkrantz K, Fridrich K, Gu\u00f0mundsd\u00f3ttir I, S\u00f8rbye SW, Bautista O, Group T, Luxembourg A, Marshall JB, Radley D, Yang YS, Badshah C, Saah A (2020) Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EClinicalMedicine 23:100401. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100401","journal-title":"EClinicalMedicine"},{"key":"1_CR75","doi-asserted-by":"publisher","unstructured":"Konopnicki D, Gilles C, Manigart Y, Barlow P, Reschner A, Necsoi C, Delforge M, Vanden Broeck D, Dauby N, De Wit S (2025) Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaf241","DOI":"10.1093\/cid\/ciaf241"},{"key":"1_CR76","unstructured":"Kreimer A (2025) State of the science on single-dose HPV vaccination. Paper presented at the American Association for Cancer Research. AACR annual meeting 2025, Chicago, IL"},{"issue":"10","key":"1_CR77","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","volume":"112","author":"AR Kreimer","year":"2020","unstructured":"Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp T, Herrero R, Wagner S, Boland J, Schussler J, Lowy DR, Chanock S, Roberson D, Sierra MS, Tsang SH, Schiffman M, Rodriguez AC, Cortes B, Gail MH, Hildesheim A, Gonzalez P, Pinto LA (2020) Evaluation of durability of a single dose of the Bivalent HPV Vaccine: the CVT trial. J Natl Cancer Inst 112(10):1038\u20131046. https:\/\/doi.org\/10.1093\/jnci\/djaa011","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1_CR78","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1002\/ijc.35345","volume":"156","author":"M Lehtinen","year":"2025","unstructured":"Lehtinen M, van Damme P, Beddows S, Pinto LA, Mariz F, Gray P, Dillner J (2025) Scientific approaches to defining HPV vaccine-induced protective immunity. Int J Cancer 156(10):1848\u20131857. https:\/\/doi.org\/10.1002\/ijc.35345","journal-title":"Int J Cancer"},{"issue":"6","key":"1_CR79","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/cid\/ciy1002","volume":"69","author":"RM Lewis","year":"2019","unstructured":"Lewis RM, Markowitz LE, Panicker G, Unger ER (2019) Seroprevalence of Human Papillomavirus 6\/11\/16\/18 among self-identified gay\/bisexual men who have sex with men, men who have sex with women, and females, United States, 2003-2010. Clin Infect Dis 69(6):1011\u20131018. https:\/\/doi.org\/10.1093\/cid\/ciy1002","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1_CR80","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/olq.0000000000001356","volume":"48","author":"RM Lewis","year":"2021","unstructured":"Lewis RM, Laprise JF, Gargano JW, Unger ER, Querec TD, Chesson HW, Brisson M, Markowitz LE (2021) Estimated prevalence and incidence of disease-associated human papillomavirus types among 15- to 59-year-olds in the United States. Sex Transm Dis 48(4):273\u2013277. https:\/\/doi.org\/10.1097\/olq.0000000000001356","journal-title":"Sex Transm Dis"},{"issue":"11","key":"1_CR81","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1073\/pnas.1012861108","volume":"108","author":"Z Li","year":"2011","unstructured":"Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X (2011) Transfer of IgG in the female genital tract by MHC class I-related neonatal fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci USA 108(11):4388\u20134393. https:\/\/doi.org\/10.1073\/pnas.1012861108","journal-title":"Proc Natl Acad Sci USA"},{"issue":"48","key":"1_CR82","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1016\/j.vaccine.2023.10.041","volume":"41","author":"J Li","year":"2023","unstructured":"Li J, Shi LW, Li K, Huang LR, Li JB, Dong YL, Li W, Ji M, Yang Q, Zhou LY, Yuan L, Yan XM, Chen JJ, Jiang ZW, Qi YY, Li RC, Li YP, Xia JL, Yu BW, Mo ZJ, Li CG (2023a) Comparison of the safety and persistence of immunogenicity of bivalent HPV16\/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: a randomized, double-blind, non-inferiority clinical trial. Vaccine 41(48):7212\u20137219. https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.041","journal-title":"Vaccine"},{"key":"1_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112750","volume":"14","author":"M Li","year":"2023","unstructured":"Li M, Zhao C, Zhao Y, Li J, Wei L (2023b) Immunogenicity, efficacy, and safety of human papillomavirus vaccine: data from China. Front Immunol 14:1112750. https:\/\/doi.org\/10.3389\/fimmu.2023.1112750","journal-title":"Front Immunol"},{"key":"1_CR84","doi-asserted-by":"publisher","unstructured":"Lo Cigno I, Calati F, Albertini S, Gariglio M (2020) Subversion of host innate immunity by human papillomavirus oncoproteins. Pathogens 9(4). https:\/\/doi.org\/10.3390\/pathogens9040292","DOI":"10.3390\/pathogens9040292"},{"issue":"6","key":"1_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29685","volume":"96","author":"I Lo Cigno","year":"2024","unstructured":"Lo Cigno I, Calati F, Girone C, Catozzo M, Gariglio M (2024) High-risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: uncovering mechanisms of immune evasion and therapeutic prospects. J Med Virol 96(6):e29685. https:\/\/doi.org\/10.1002\/jmv.29685","journal-title":"J Med Virol"},{"issue":"24","key":"1_CR86","doi-asserted-by":"publisher","first-page":"13253","DOI":"10.1128\/jvi.06093-11","volume":"85","author":"S Longet","year":"2011","unstructured":"Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D (2011) A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 85(24):13253\u201313259. https:\/\/doi.org\/10.1128\/jvi.06093-11","journal-title":"J Virol"},{"issue":"1","key":"1_CR87","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41541-023-00613-1","volume":"8","author":"C Loos","year":"2023","unstructured":"Loos C, Coccia M, Didierlaurent AM, Essaghir A, Fallon JK, Lauffenburger D, Luedemann C, Michell A, van der Most R, Zhu AL, Alter G, Burny W (2023) Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design. NPJ Vaccines 8(1):34. https:\/\/doi.org\/10.1038\/s41541-023-00613-1","journal-title":"NPJ Vaccines"},{"issue":"23","key":"1_CR88","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1016\/j.vaccine.2022.02.061","volume":"40","author":"H Lv","year":"2022","unstructured":"Lv H, Wang S, Liang Z, Yu W, Yan C, Chen Y, Hu X, Fu R, Zheng M, Group T, Luxembourg A, Liao X, Chen Z (2022) Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: a phase 3 open-label study. Vaccine 40(23):3263\u20133271. https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.061","journal-title":"Vaccine"},{"issue":"2","key":"1_CR89","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/bab.2128","volume":"69","author":"S Mahmoudvand","year":"2022","unstructured":"Mahmoudvand S, Shokri S, Makvandi M, Taherkhani R, Rashno M, Jalilian FA, Angali KA (2022) In silico prediction of T-cell and B-cell epitopes of human papillomavirus type 16 L1 protein. Biotechnol Appl Biochem 69(2):514\u2013525. https:\/\/doi.org\/10.1002\/bab.2128","journal-title":"Biotechnol Appl Biochem"},{"issue":"1","key":"1_CR90","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-020-0165-x","volume":"5","author":"FC Mariz","year":"2020","unstructured":"Mariz FC, Bender N, Anantharaman D, Basu P, Bhatla N, Pillai MR, Prabhu PR, Sankaranarayanan R, Eriksson T, Pawlita M, Prager K, Sehr P, Waterboer T, M\u00fcller M, Lehtinen M (2020) Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6\/16\/18\/31\/33\/45\/52\/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines 5(1):14. https:\/\/doi.org\/10.1038\/s41541-020-0165-x","journal-title":"NPJ Vaccines"},{"issue":"10","key":"1_CR91","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/s1473-3099(20)30873-2","volume":"21","author":"FC Mariz","year":"2021","unstructured":"Mariz FC, Gray P, Bender N, Eriksson T, Kann H, Apter D, Paavonen J, Pajunen E, Prager KM, Sehr P, Surcel HM, Waterboer T, M\u00fcller M, Pawlita M, Lehtinen M (2021) Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. Lancet Infect Dis 21(10):1458\u20131468. https:\/\/doi.org\/10.1016\/s1473-3099(20)30873-2","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"1_CR92","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/infdis\/jiz555","volume":"221","author":"LE Markowitz","year":"2020","unstructured":"Markowitz LE, Naleway AL, Klein NP, Lewis RM, Crane B, Querec TD, Hsiao A, Aukes L, Timbol J, Weinmann S, Liu G, Steinau M, Unger ER (2020) Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses. J Infect Dis 221(6):910\u2013918. https:\/\/doi.org\/10.1093\/infdis\/jiz555","journal-title":"J Infect Dis"},{"issue":"9","key":"1_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137195","volume":"10","author":"K Matsui","year":"2015","unstructured":"Matsui K, Adelsberger JW, Kemp TJ, Baseler MW, Ledgerwood JE, Pinto LA (2015) Circulating CXCR5+CD4+ T follicular-like helper cell and memory B cell responses to human papillomavirus vaccines. PLoS One 10(9):e0137195. https:\/\/doi.org\/10.1371\/journal.pone.0137195","journal-title":"PLoS One"},{"key":"1_CR94","doi-asserted-by":"publisher","unstructured":"Matsui K, Hempel HA, Shelton G, Ocampo R, Kemp TJ, Pan Y, Pinto LA (2024) Reproducibility assessment of enzyme-linked immunosorbent assays to detect anti-HPV16 L1-specific IgG1, IgG3, IgA, and IgM antibodies. Vaccines 12(10). https:\/\/doi.org\/10.3390\/vaccines12101108","DOI":"10.3390\/vaccines12101108"},{"issue":"12","key":"1_CR95","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/infdis\/jiaa306","volume":"222","author":"E Meites","year":"2020","unstructured":"Meites E, Winer RL, Newcomb ME, Gorbach PM, Querec TD, Rudd J, Collins T, Lin J, Moore J, Remble T, Swanson F, Franz J, Bolan RK, Golden MR, Mustanski B, Crosby RA, Unger ER, Markowitz LE (2020) Vaccine effectiveness against prevalent anal and oral human papillomavirus infection among men who have sex with men-United States, 2016-2018. J Infect Dis 222(12):2052\u20132060. https:\/\/doi.org\/10.1093\/infdis\/jiaa306","journal-title":"J Infect Dis"},{"issue":"37","key":"1_CR96","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1016\/j.vaccine.2021.07.069","volume":"39","author":"CN Miller","year":"2021","unstructured":"Miller CN, Kemp TJ, Abrahamsen M, Isaacs-Soriano K, Dunham K, Sirak B, Pan Y, Lazcano-Ponce E, Salmeron J, Pinto LA, Giuliano AR (2021) Increases in HPV-16\/18 antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccine. Vaccine 39(37):5295\u20135301. https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.069","journal-title":"Vaccine"},{"issue":"14","key":"1_CR97","doi-asserted-by":"publisher","first-page":"7616","DOI":"10.3390\/ijms25147616","volume":"25","author":"B Mlynarczyk-Bonikowska","year":"2024","unstructured":"Mlynarczyk-Bonikowska B, Rudnicka L (2024) HPV infections-classification, pathogenesis, and potential new therapies. Int J Mol Sci 25(14):7616. https:\/\/doi.org\/10.3390\/ijms25147616","journal-title":"Int J Mol Sci"},{"issue":"20","key":"1_CR98","first-page":"613","volume":"59","author":"MMWR","year":"2010","unstructured":"MMWR (2010) Differences by sex in tobacco use and awareness of tobacco marketing\u2014Bangladesh, Thailand, and Uruguay, 2009. MMWR Morb Mortal Wkly Rep 59(20):613\u2013618","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"1_CR99","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3390\/v14081797","volume":"14","author":"CA Moody","year":"2022","unstructured":"Moody CA (2022) Regulation of the innate immune response during the human papillomavirus life cycle. Viruses 14(8):1797. https:\/\/doi.org\/10.3390\/v14081797","journal-title":"Viruses"},{"issue":"4","key":"1_CR100","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.vaccine.2014.11.047","volume":"33","author":"PL Moro","year":"2015","unstructured":"Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI et al (2015) Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006\u20132013. Vaccine 33(4):519\u2013522","journal-title":"Vaccine"},{"issue":"1","key":"1_CR101","doi-asserted-by":"publisher","first-page":"15225","DOI":"10.1038\/s41598-019-51679-8","volume":"9","author":"A Namvar","year":"2019","unstructured":"Namvar A, Bolhassani A, Javadi G, Noormohammadi Z (2019) In silico\/in vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine. Sci Rep 9(1):15225. https:\/\/doi.org\/10.1038\/s41598-019-51679-8","journal-title":"Sci Rep"},{"issue":"15","key":"1_CR102","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/jnci\/djg018","volume":"95","author":"D Nardelli-Haefliger","year":"2003","unstructured":"Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P (2003) Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95(15):1128\u20131137. https:\/\/doi.org\/10.1093\/jnci\/djg018","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1_CR103","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.4161\/hv.29532","volume":"10","author":"PS Naud","year":"2014","unstructured":"Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D (2014) Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 10(8):2147\u20132162. https:\/\/doi.org\/10.4161\/hv.29532","journal-title":"Hum Vaccin Immunother"},{"key":"1_CR104","doi-asserted-by":"publisher","unstructured":"Nicoli F, Mantelli B, Gallerani E, Telatin V, Bonazzi I, Marconi P, Gavioli R, Gabrielli L, Lazzarotto T, Barzon L, Pal\u00f9 G, Caputo AA (2020) HPV-specific systemic antibody responses and memory B cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with Cervarix and Gardasil in adolescent and young adult women in vaccination programs in Italy. Vaccines 8(1). https:\/\/doi.org\/10.3390\/vaccines8010026","DOI":"10.3390\/vaccines8010026"},{"issue":"1","key":"1_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00458-0","volume":"7","author":"F Nicoli","year":"2022","unstructured":"Nicoli F, Mantelli B, Gallerani E, Telatin V, Squarzon L, Masiero S, Gavioli R, Pal\u00f9 G, Barzon L, Caputo A (2022) Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine. NPJ Vaccines 7(1):37. https:\/\/doi.org\/10.1038\/s41541-022-00458-0","journal-title":"NPJ Vaccines"},{"issue":"5","key":"1_CR106","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1128\/cvi.00348-09","volume":"17","author":"D Opalka","year":"2010","unstructured":"Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT (2010) Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 17(5):818\u2013827. https:\/\/doi.org\/10.1128\/cvi.00348-09","journal-title":"Clin Vaccine Immunol"},{"issue":"Pt 9","key":"1_CR107","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1099\/vir.0.032011-0","volume":"92","author":"AE Paaso","year":"2011","unstructured":"Paaso AE, Louvanto K, Syrj\u00e4nen KJ, Waterboer T, Gr\u00e9nman SE, Pawlita M, Syrj\u00e4nen SM (2011) Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. J Gen Virol 92(Pt 9):2034\u20132046. https:\/\/doi.org\/10.1099\/vir.0.032011-0","journal-title":"J Gen Virol"},{"key":"1_CR108","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12967-015-0498-9","volume":"13","author":"A Paaso","year":"2015","unstructured":"Paaso A, Koskimaa HM, Welters MJ, Gr\u00e9nman S, Syrj\u00e4nen K, van der Burg SH, Syrj\u00e4nen S (2015) Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years. J Transl Med 13:163. https:\/\/doi.org\/10.1186\/s12967-015-0498-9","journal-title":"J Transl Med"},{"issue":"3","key":"1_CR109","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/jnci\/91.3.226","volume":"91","author":"JM Palefsky","year":"1999","unstructured":"Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, Young M, Melnick S, Miotti P, Burk R (1999) Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 91(3):226\u2013236. https:\/\/doi.org\/10.1093\/jnci\/91.3.226","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1_CR110","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.vaccine.2023.01.008","volume":"41","author":"I Park","year":"2023","unstructured":"Park I, Unger ER, Kemp TJ, Pinto LA (2023) The second HPV serology meeting: Progress and challenges in standardization of human papillomavirus serology assays. Vaccine 41(6):1177\u20131181. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.008","journal-title":"Vaccine"},{"issue":"49","key":"1_CR111","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.1016\/j.vaccine.2019.09.066","volume":"37","author":"H Pasmans","year":"2019","unstructured":"Pasmans H, Schurink-Van\u2019t Klooster TM, Bogaard MJM, van Rooijen DM, de Melker HE, Welters MJP, van der Burg SH, van der Klis FRM, Buisman AM (2019) Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls. Vaccine 37(49):7280\u20137288. https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.066","journal-title":"Vaccine"},{"key":"1_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863164","volume":"13","author":"H Pasmans","year":"2022","unstructured":"Pasmans H, Berkowska MA, Diks AM, de Mooij B, Groenland RJ, de Rond L, Nicolaie MA, van der Burg SH, van Dongen JJM, van der Klis FRM, Buisman AM (2022) Characterization of the early cellular immune response induced by HPV vaccines. Front Immunol 13:863164. https:\/\/doi.org\/10.3389\/fimmu.2022.863164","journal-title":"Front Immunol"},{"issue":"2","key":"1_CR113","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.virol.2003.12.027","volume":"321","author":"DV Pastrana","year":"2004","unstructured":"Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kr\u00fcger Kjaer S, Lowy DR, Schiller JT (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321(2):205\u2013216. https:\/\/doi.org\/10.1016\/j.virol.2003.12.027","journal-title":"Virology"},{"key":"1_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2019.100185","volume":"8","author":"J Pattyn","year":"2019","unstructured":"Pattyn J, Van Keer S, Tjalma W, Matheeussen V, Van Damme P, Vorsters A (2019) Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus Res 8:100185. https:\/\/doi.org\/10.1016\/j.pvr.2019.100185","journal-title":"Papillomavirus Res"},{"issue":"6","key":"1_CR115","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","volume":"40","author":"C Pedersen","year":"2007","unstructured":"Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G (2007) Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40(6):564\u2013571. https:\/\/doi.org\/10.1016\/j.jadohealth.2007.02.015","journal-title":"J Adolesc Health"},{"issue":"1","key":"1_CR116","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","volume":"44","author":"T Pet\u00e4j\u00e4","year":"2009","unstructured":"Pet\u00e4j\u00e4 T, Ker\u00e4nen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M, Lev\u00e4nen H, Tocklin T, Godeaux O, Lehtinen M, Dubin G (2009) Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 44(1):33\u201340. https:\/\/doi.org\/10.1016\/j.jadohealth.2008.10.002","journal-title":"J Adolesc Health"},{"key":"1_CR117","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pvr.2017.03.002","volume":"3","author":"LK Petersen","year":"2017","unstructured":"Petersen LK, Restrepo J, Moreira ED Jr, Iversen OE, Pitisuttithum P, Van Damme P, Joura EA, Olsson SE, Ferris D, Block S, Giuliano AR, Bosch X, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Hyatt D, Maansson R, Moeller E, Qi H, Roberts C, Luxembourg A (2017) Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - a combined analysis of five phase III clinical trials. Papillomavirus Res 3:105\u2013115. https:\/\/doi.org\/10.1016\/j.pvr.2017.03.002","journal-title":"Papillomavirus Res"},{"issue":"Pt 3","key":"1_CR118","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1099\/0022-1317-81-3-701","volume":"81","author":"A Petter","year":"2000","unstructured":"Petter A, Heim K, Guger M, Ciresa-K\u00f6 Nig A, Christensen N, Sarcletti M, Wieland U, Pfister H, Zangerle R, H\u00f6pfl R (2000) Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. J Gen Virol 81(Pt 3):701\u2013708. https:\/\/doi.org\/10.1099\/0022-1317-81-3-701","journal-title":"J Gen Virol"},{"issue":"2","key":"1_CR119","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/376505","volume":"188","author":"LA Pinto","year":"2003","unstructured":"Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A (2003) Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 188(2):327\u2013338. https:\/\/doi.org\/10.1086\/376505","journal-title":"J Infect Dis"},{"issue":"27","key":"1_CR120","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1016\/j.vaccine.2005.01.146","volume":"23","author":"LA Pinto","year":"2005","unstructured":"Pinto LA, Castle PE, Roden RB, Harro CD, Lowy DR, Schiller JT, Wallace D, Williams M, Kopp W, Frazer IH, Berzofsky JA, Hildesheim A (2005) HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 23(27):3555\u20133564. https:\/\/doi.org\/10.1016\/j.vaccine.2005.01.146","journal-title":"Vaccine"},{"issue":"32 Pt a","key":"1_CR121","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1016\/j.vaccine.2017.11.089","volume":"36","author":"LA Pinto","year":"2018","unstructured":"Pinto LA, Dillner J, Beddows S, Unger ER (2018) Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development. Vaccine 36(32 Pt a):4792\u20134799. https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.089","journal-title":"Vaccine"},{"issue":"11","key":"1_CR122","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/14787210.2017.1392854","volume":"15","author":"M Poljak","year":"2017","unstructured":"Poljak M, \u0160terbenc A, Lunar MM (2017) Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV). Expert Rev Anti-Infect Ther 15(11):987\u2013999. https:\/\/doi.org\/10.1080\/14787210.2017.1392854","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"6","key":"1_CR123","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/imcb.12636","volume":"101","author":"C Poloni","year":"2023","unstructured":"Poloni C, Schonhofer C, Ivison S, Levings MK, Steiner TS, Cook L (2023) T-cell activation-induced marker assays in health and disease. Immunol Cell Biol 101(6):491\u2013503. https:\/\/doi.org\/10.1111\/imcb.12636","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"1_CR124","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.vaccine.2021.11.041","volume":"40","author":"C Porras","year":"2022","unstructured":"Porras C, Sampson JN, Herrero R, Gail MH, Cort\u00e9s B, Hildesheim A, Cyr J, Romero B, Schiller JT, Montero C, Pinto LA, Schussler J, Coronado K, Sierra MS, Kim JJ, Torres CM, Carvajal L, Wagner S, Campos NG, Ocampo R, Kemp TJ, Zuniga M, Lowy DR, Avila C, Chanock S, Castrillo A, Estrada Y, Barrientos G, Monge C, Oconitrillo MY, Kreimer AR (2022) Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: the Costa Rica ESCUDDO trial. Vaccine 40(1):76\u201388. https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.041","journal-title":"Vaccine"},{"issue":"67","key":"1_CR125","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jncimonographs\/lgae032","volume":"2024","author":"C Porras","year":"2024","unstructured":"Porras C, Romero B, Kemp T, Fantin R, Herrero R, Hildesheim A, Ocampo R, Sierra MS, Gail MH, Schussler J, Schiller JT, Lowy DR, Pinto LA, Liu D, Kreimer AR (2024) HPV16\/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial. J Natl Cancer Inst Monogr 2024(67):329\u2013336. https:\/\/doi.org\/10.1093\/jncimonographs\/lgae032","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"10","key":"1_CR126","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.it.2022.07.011","volume":"43","author":"C Quang","year":"2022","unstructured":"Quang C, Chung AW, Frazer IH, Toh ZQ, Licciardi PV (2022) Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies? Trends Immunol 43(10):815\u2013825. https:\/\/doi.org\/10.1016\/j.it.2022.07.011","journal-title":"Trends Immunol"},{"issue":"6","key":"1_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29732","volume":"96","author":"C Quang","year":"2024","unstructured":"Quang C, Chung AW, Kemp TJ, Ratu T, Tuivaga E, Russell FM, Licciardi PV, Toh ZQ (2024) Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies. J Med Virol 96(6):e29732. https:\/\/doi.org\/10.1002\/jmv.29732","journal-title":"J Med Virol"},{"issue":"1","key":"1_CR128","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1038\/s41467-025-57443-z","volume":"16","author":"C Quang","year":"2025","unstructured":"Quang C, Anderson J, Russell FM, Reyburn R, Ratu T, Tuivaga E, Devi R, Frazer IH, Garland SM, Wines B, Hogarth PM, Mulholland K, Chung AW, Toh ZQ, Licciardi PV (2025) Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine. Nat Commun 16(1):2130. https:\/\/doi.org\/10.1038\/s41467-025-57443-z","journal-title":"Nat Commun"},{"issue":"4","key":"1_CR129","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060993","volume":"152","author":"J Restrepo","year":"2023","unstructured":"Restrepo J, Herrera T, Samakoses R, Reina JC, Pitisuttithum P, Ulied A, Bekker LG, Moreira ED, Olsson SE, Block SL, Hammes LS, Laginha F, Ferenczy A, Kurman R, Ronnett BM, Stoler M, Bautista O, Gallagher NE, Salituro G, Ye M, Luxembourg A (2023) Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety. Pediatrics 152(4):e2022060993. https:\/\/doi.org\/10.1542\/peds.2022-060993","journal-title":"Pediatrics"},{"issue":"10","key":"1_CR130","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1002\/cam4.1879","volume":"8","author":"D Rosillon","year":"2019","unstructured":"Rosillon D, Baril L, Del Rosario-Raymundo MR, Wheeler CM, Skinner SR, Garland SM, Salmeron J, Lazcano-Ponce E, Vallejos CS, Stoney T, Ter Harmsel B, Lim TYK, Quek SC, Minkina G, McNeil SA, Bouchard C, Fong KL, Money D, Ilancheran A, Savicheva A, Cruickshank M, Chatterjee A, Fiander A, Martens M, Bozonnat MC, Struyf F, Dubin G, Castellsagu\u00e9 X (2019) Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16\/18 antibodies. Cancer Med 8(10):4938\u20134953. https:\/\/doi.org\/10.1002\/cam4.1879","journal-title":"Cancer Med"},{"issue":"1","key":"1_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00628-8","volume":"8","author":"V Roy","year":"2023","unstructured":"Roy V, Jung W, Linde C, Coates E, Ledgerwood J, Costner P, Yamshchikov G, Streeck H, Juelg B, Lauffenburger DA, Alter G (2023) Differences in HPV-specific antibody Fc-effector functions following Gardasil\u00ae and Cervarix\u00ae vaccination. NPJ Vaccines 8(1):39. https:\/\/doi.org\/10.1038\/s41541-023-00628-8","journal-title":"NPJ Vaccines"},{"issue":"9","key":"1_CR132","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/olq.0000000000001416","volume":"48","author":"MT Ruffin","year":"2021","unstructured":"Ruffin MT, Hade EM, Fahey P, Christian LM, Paskett ED, Harper DM (2021) Predictors of human papillomavirus seropositivity in Appalachian women aged 18 to 26 years. Sex Transm Dis 48(9):693\u2013699. https:\/\/doi.org\/10.1097\/olq.0000000000001416","journal-title":"Sex Transm Dis"},{"issue":"21","key":"1_CR133","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/jnci\/djq384","volume":"102","author":"M Safaeian","year":"2010","unstructured":"Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A (2010) Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and \u221218 infections. J Natl Cancer Inst 102(21):1653\u20131662. https:\/\/doi.org\/10.1093\/jnci\/djq384","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1_CR134","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1158\/1940-6207.Capr-13-0203","volume":"6","author":"M Safaeian","year":"2013","unstructured":"Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA (2013) Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine trial. Cancer Prev Res (Phila) 6(11):1242\u20131250. https:\/\/doi.org\/10.1158\/1940-6207.Capr-13-0203","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"1_CR135","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/infdis\/jiy112","volume":"218","author":"M Safaeian","year":"2018","unstructured":"Safaeian M, Castellsagu\u00e9 X, Hildesheim A, Wacholder S, Schiffman MH, Bozonnat MC, Baril L, Rosillon D (2018a) Risk of HPV-16\/18 infections and associated cervical abnormalities in women seropositive for naturally acquired antibodies: pooled analysis based on control arms of two large clinical trials. J Infect Dis 218(1):84\u201394. https:\/\/doi.org\/10.1093\/infdis\/jiy112","journal-title":"J Infect Dis"},{"issue":"2","key":"1_CR136","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/djx158","volume":"110","author":"M Safaeian","year":"2018","unstructured":"Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, van Doorn LJ, Schussler J, Lowy DR, Schiller J, Schiffman MT, Rodriguez AC, Gail MH, Hildesheim A, Gonzalez P, Pinto LA, Kreimer AR (2018b) Durability of protection afforded by fewer doses of the HPV16\/18 Vaccine: the CVT trial. J Natl Cancer Inst 110(2):205\u2013212. https:\/\/doi.org\/10.1093\/jnci\/djx158","journal-title":"J Natl Cancer Inst"},{"key":"1_CR137","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ebiom.2016.06.042","volume":"10","author":"EM Scherer","year":"2016","unstructured":"Scherer EM, Smith RA, Gallego DF, Carter JJ, Wipf GC, Hoyos M, Stern M, Thurston T, Trinklein ND, Wald A, Galloway DA (2016) A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects. EBioMedicine 10:55\u201364. https:\/\/doi.org\/10.1016\/j.ebiom.2016.06.042","journal-title":"EBioMedicine"},{"issue":"2","key":"1_CR138","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4161\/hv.22693","volume":"9","author":"M Scherpenisse","year":"2013","unstructured":"Scherpenisse M, Mollers M, Schepp RM, Meijer CJ, de Melker HE, Berbers GA, van der Klis FR (2013a) Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination. Hum Vaccin Immunother 9(2):314\u2013321. https:\/\/doi.org\/10.4161\/hv.22693","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"1_CR139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074797","volume":"8","author":"M Scherpenisse","year":"2013","unstructured":"Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, van der Klis FR (2013b) Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One 8(9):e74797. https:\/\/doi.org\/10.1371\/journal.pone.0074797","journal-title":"PLoS One"},{"key":"1_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102331","volume":"35","author":"AE Schuind","year":"2023","unstructured":"Schuind AE, Rees H, Schiller J, Mugo N, Dull P, Barnabas R, Clifford GM, Liu G, Madhi SA, Morse RB, Moscicki AB, Palefsky JM, Plotkin S, Sierra MS, Slifka MK, Vorsters A, Kreimer AR, Didierlaurent AM (2023) State-of-the-science of human papillomavirus vaccination in women with human immunodeficiency virus: summary of a scientific workshop. Prev Med Rep 35:102331. https:\/\/doi.org\/10.1016\/j.pmedr.2023.102331","journal-title":"Prev Med Rep"},{"issue":"12","key":"1_CR141","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.4161\/hv.6.12.13399","volume":"6","author":"TF Schwarz","year":"2010","unstructured":"Schwarz TF, Kocken M, Pet\u00e4j\u00e4 T, Einstein MH, Spaczynski M, Louwers JA, Pedersen C, Levin M, Zahaf T, Poncelet S, Hardt K, Descamps D, Dubin G (2010) Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16\/18 AS04-adjuvanted vaccine. Hum Vaccin 6(12):1054\u20131061. https:\/\/doi.org\/10.4161\/hv.6.12.13399","journal-title":"Hum Vaccin"},{"issue":"12","key":"1_CR142","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/s1470-2045(23)00480-1","volume":"24","author":"H Sharma","year":"2023","unstructured":"Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N et al (2023) Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2\/3 trial. Lancet Oncol 24(12):1321\u20131333. https:\/\/doi.org\/10.1016\/s1470-2045(23)00480-1","journal-title":"Lancet Oncol"},{"key":"1_CR143","doi-asserted-by":"publisher","unstructured":"Shing JZ, Giuliano AR, Brenner NL, Michels B, Hildesheim A, Srivastava S, Sirak BA, Schussler J, Liu D, Wang W, Waterboer T, Kreimer AR (2024) Natural history of HPV16-E6 serology among cancer-free men in a multicenter longitudinal cohort study. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djae326","DOI":"10.1093\/jnci\/djae326"},{"issue":"1","key":"1_CR144","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/B978-1-4160-3611-1.50006-4","volume":"5","author":"C-A Siegrist","year":"2008","unstructured":"Siegrist C-A (2008) Vaccine immunology. Vaccines 5(1):17\u201336","journal-title":"Vaccines"},{"issue":"6","key":"1_CR145","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jadohealth.2011.03.010","volume":"48","author":"JS Smith","year":"2011","unstructured":"Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM (2011) Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health 48(6):540\u2013552. https:\/\/doi.org\/10.1016\/j.jadohealth.2011.03.010","journal-title":"J Adolesc Health"},{"issue":"2","key":"1_CR146","doi-asserted-by":"publisher","first-page":"101","DOI":"10.22088\/ijmcm.Bums.10.2.101","volume":"10","author":"M Soliman","year":"2021","unstructured":"Soliman M, Oredein O, Dass CR (2021) Update on safety and efficacy of HPV vaccines: focus on Gardasil. Int J Mol Cell Med 10(2):101\u2013113. https:\/\/doi.org\/10.22088\/ijmcm.Bums.10.2.101","journal-title":"Int J Mol Cell Med"},{"issue":"1 Suppl","key":"1_CR147","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ygyno.2010.04.002","volume":"118","author":"M Stanley","year":"2010","unstructured":"Stanley M (2010) Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol 118(1 Suppl):S2\u2013S7. https:\/\/doi.org\/10.1016\/j.ygyno.2010.04.002","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1_CR148","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1128\/cmr.05028-11","volume":"25","author":"MA Stanley","year":"2012","unstructured":"Stanley MA (2012) Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 25(2):215\u2013222. https:\/\/doi.org\/10.1128\/cmr.05028-11","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 5","key":"1_CR149","doi-asserted-by":"publisher","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","volume":"30","author":"M Stanley","year":"2012","unstructured":"Stanley M, Pinto LA, Trimble C (2012) Human papillomavirus vaccines\u2014immune responses. Vaccine 30(Suppl 5):F83\u2013F87. https:\/\/doi.org\/10.1016\/j.vaccine.2012.04.106","journal-title":"Vaccine"},{"issue":"Pt 6","key":"1_CR150","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1099\/vir.0.007823-0","volume":"90","author":"S Syrj\u00e4nen","year":"2009","unstructured":"Syrj\u00e4nen S, Waterboer T, Sarkola M, Michael K, Rintala M, Syrj\u00e4nen K, Grenman S, Pawlita M (2009) Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol 90(Pt 6):1515\u20131526. https:\/\/doi.org\/10.1099\/vir.0.007823-0","journal-title":"J Gen Virol"},{"issue":"1","key":"1_CR151","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41598-022-06343-z","volume":"12","author":"S Syrj\u00e4nen","year":"2022","unstructured":"Syrj\u00e4nen S, Waterboer T, Rintala M, Pawlita M, Syrj\u00e4nen K, Louvanto K, Grenman S (2022) Maternal HPV-antibodies and seroconversion to HPV in children during the first 3 years of life. Sci Rep 12(1):2227. https:\/\/doi.org\/10.1038\/s41598-022-06343-z","journal-title":"Sci Rep"},{"issue":"12","key":"1_CR152","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.oraloncology.2015.10.011","volume":"51","author":"RP Takes","year":"2015","unstructured":"Takes RP, Wierzbicka M, D\u2019Souza G, Jackowska J, Silver CE, Rodrigo JP, Dikkers FG, Olsen KD, Rinaldo A, Brakenhoff RH, Ferlito A (2015) HPV vaccination to prevent oropharyngeal carcinoma: what can be learned from anogenital vaccination programs? Oral Oncol 51(12):1057\u20131060. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.10.011","journal-title":"Oral Oncol"},{"issue":"3","key":"1_CR153","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.mcna.2015.01.003","volume":"99","author":"L Thaxton","year":"2015","unstructured":"Thaxton L, Waxman AG (2015) Cervical cancer prevention: immunization and screening 2015. Med Clin North Am 99(3):469\u2013477. https:\/\/doi.org\/10.1016\/j.mcna.2015.01.003","journal-title":"Med Clin North Am"},{"key":"1_CR154","volume-title":"China approves first domestically produced 9-valent HPV vaccine","author":"The State Council Information Office The People\u2019s Republic of China","year":"2025","unstructured":"The State Council Information Office The People\u2019s Republic of China (2025). China approves first domestically produced 9-valent HPV vaccine. Available from: http:\/\/english.scio.gov.cn\/pressroom\/2025-05\/30\/content_117904321.html"},{"key":"1_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100220","volume":"13","author":"T Tian","year":"2021","unstructured":"Tian T, Fu L, Lin YF, Zou H (2021) Potential role of naturally acquired immunity against HPV in the control of HPV related diseases. Lancet Reg Health West Pac 13:100220. https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100220","journal-title":"Lancet Reg Health West Pac"},{"issue":"8","key":"1_CR156","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/infdis\/jit657","volume":"209","author":"L Toft","year":"2014","unstructured":"Toft L, Storgaard M, M\u00fcller M, Sehr P, Bonde J, Tolstrup M, \u00d8stergaard L, S\u00f8gaard OS (2014a) Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 209(8):1165\u20131173. https:\/\/doi.org\/10.1093\/infdis\/jit657","journal-title":"J Infect Dis"},{"issue":"5","key":"1_CR157","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.4161\/hv.27925","volume":"10","author":"L Toft","year":"2014","unstructured":"Toft L, Tolstrup M, M\u00fcller M, Sehr P, Bonde J, Storgaard M, \u00d8stergaard L, S\u00f8gaard OS (2014b) Comparison of the immunogenicity of Cervarix\u00ae and Gardasil\u00ae human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Hum Vaccin Immunother 10(5):1147\u20131154. https:\/\/doi.org\/10.4161\/hv.27925","journal-title":"Hum Vaccin Immunother"},{"key":"1_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585768","volume":"11","author":"ZQ Toh","year":"2020","unstructured":"Toh ZQ, He L, Chen C, Huang A, Russell FM, Garland SM, Reyburn R, Ratu T, Tuivaga E, Frazer IH, Mulholland EK, Licciardi PV (2020) Measurement of human papillomavirus-specific antibodies using a Pseudovirion-based ELISA method. Front Immunol 11:585768. https:\/\/doi.org\/10.3389\/fimmu.2020.585768","journal-title":"Front Immunol"},{"issue":"7","key":"1_CR159","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/cid\/ciab603","volume":"74","author":"JE Tota","year":"2022","unstructured":"Tota JE, Giuliano AR, Goldstone SE, Dubin B, Saah A, Luxembourg A, Velicer C, Palefsky JM (2022) Anogenital human papillomavirus (HPV) infection, seroprevalence, and risk factors for HPV seropositivity among sexually active men enrolled in a global HPV vaccine trial. Clin Infect Dis 74(7):1247\u20131256. https:\/\/doi.org\/10.1093\/cid\/ciab603","journal-title":"Clin Infect Dis"},{"issue":"38","key":"1_CR160","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1016\/j.vaccine.2020.07.017","volume":"38","author":"SH Tsang","year":"2020","unstructured":"Tsang SH, Basu P, Bender N, Herrero R, Kemp TJ, Kreimer AR, M\u00fcller M, Panicker G, Pawlita M, Pinto LA, Sampson JN, Sankaranarayanan R, Schussler J, Sehr P, Sierra MS, Unger ER, Waterboer T, Hildesheim A (2020) Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. Vaccine 38(38):5997\u20136006. https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.017","journal-title":"Vaccine"},{"issue":"1","key":"1_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00431-x","volume":"7","author":"SH Tsang","year":"2022","unstructured":"Tsang SH, Schiller JT, Porras C, Kemp TJ, Herrero R, Schussler J, Sierra MS, Cortes B, Hildesheim A, Lowy DR, Rodr\u00edguez AC, Romero B, \u00c7uburu N, Shing JZ, Pinto LA, Sampson JN, Kreimer AR (2022) HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. NPJ Vaccines 7(1):40. https:\/\/doi.org\/10.1038\/s41541-022-00431-x","journal-title":"NPJ Vaccines"},{"issue":"5","key":"1_CR162","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/sti.74.5.354","volume":"74","author":"G van Doornum","year":"1998","unstructured":"van Doornum G, Prins M, Andersson-Ellstr\u00f6m A, Dillner J (1998) Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. Sex Transm Infect 74(5):354\u2013360. https:\/\/doi.org\/10.1136\/sti.74.5.354","journal-title":"Sex Transm Infect"},{"issue":"8","key":"1_CR163","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2174\/1389450123666211221160632","volume":"23","author":"R Vanajothi","year":"2022","unstructured":"Vanajothi R, Srikanth N, Vijayakumar R, Palanisamy M, Bhavaniramya S, Premkumar K (2022) HPV-mediated cervical cancer: a systematic review on immunological basis, molecular biology, and immune evasion mechanisms. Curr Drug Targets 23(8):782\u2013801. https:\/\/doi.org\/10.2174\/1389450123666211221160632","journal-title":"Curr Drug Targets"},{"key":"1_CR164","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1186\/s12879-014-0676-z","volume":"14","author":"LS Velentzis","year":"2014","unstructured":"Velentzis LS, Sitas F, O\u2019Connell DL, Darlington-Brown J, Egger S, Sinha R, Banks E, Frazer IH, Canfell K (2014) Human papillomavirus 16\/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study. BMC Infect Dis 14:3861. https:\/\/doi.org\/10.1186\/s12879-014-0676-z","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1_CR165","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-022-01717-x","volume":"22","author":"S Vuorinen","year":"2022","unstructured":"Vuorinen S, Syrj\u00e4nen K, Waterboer T, Gr\u00e9nman S, Syrj\u00e4nen S, Louvanto K (2022) Outcomes of HPV type-specific serostatus do not associate with oral or genital HPV-carriage in non-vaccinated women followed for three years. BMC Womens Health 22(1):141. https:\/\/doi.org\/10.1186\/s12905-022-01717-x","journal-title":"BMC Womens Health"},{"key":"1_CR166","unstructured":"Walvax (2022) Recombinant human papillomavirus bivalent (types 16,18) vaccine (Pichia pastoris) [package insert]. Yuxi Zerun Biotechnology Co., Ltd., Yunnan Province, P.R. China"},{"issue":"2","key":"1_CR167","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1586\/erv.12.151","volume":"12","author":"JW Wang","year":"2013","unstructured":"Wang JW, Roden RB (2013) Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines 12(2):129\u2013141. https:\/\/doi.org\/10.1586\/erv.12.151","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"1_CR168","first-page":"442","volume":"32","author":"A Wang","year":"2016","unstructured":"Wang A, Jiang M, Li N, Zhang G, Qi Y, Liu Y, Xi Y, Zhou J (2016) Prediction of B cell epitopes of human papillomavirus type 16 L1 protein. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 32(4):442\u2013445","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"issue":"10","key":"1_CR169","doi-asserted-by":"publisher","first-page":"e1473","DOI":"10.1016\/s2214-109x(22)00309-6","volume":"10","author":"D Watson-Jones","year":"2022","unstructured":"Watson-Jones D, Changalucha J, Whitworth H, Pinto L, Mutani P, Indangasi J, Kemp T, Hashim R, Kamala B, Wiggins R, Songoro T, Connor N, Mbwanji G, Pavon MA, Lowe B, Mmbando D, Kapiga S, Mayaud P, de SanJos\u00e9 S, Dillner J, Hayes RJ, Lacey CJ, Baisley K (2022) Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. Lancet Glob Health 10(10):e1473\u2013e1484. https:\/\/doi.org\/10.1016\/s2214-109x(22)00309-6","journal-title":"Lancet Glob Health"},{"key":"1_CR170","doi-asserted-by":"publisher","unstructured":"Watson-Jones D, Changalucha J, Maxwell C, Whitworth H, Mutani P, Kemp TJ, Kamala B, Indangasi J, Constantine G, Hashim R, Mwanzalima D, Wiggins R, Mmbando D, Connor N, Pavon MA, Lowe B, Kapiga S, Mayaud P, de Sanjos\u00e9 S, Dillner J, Hayes RJ, Lacey CJ, Pinto L, Baisley K (2025) Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9\u201314 years: results of the long-term extension of the DoRIS randomised trial. Lancet Glob Health 13(2):e319-e328. doi:https:\/\/doi.org\/10.1016\/s2214-109x(24)00477-7","DOI":"10.1016\/s2214-109x(24)00477-7"},{"issue":"5","key":"1_CR171","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00405-024-08537-9","volume":"281","author":"T Weiland","year":"2024","unstructured":"Weiland T, Zgubic J, Brcic L, Thurnher D (2024) Detection of antibody subclasses IgA, IgM and IgG against HPV L1 in HPV-positive oropharyngeal squamous cell carcinoma patients: a pilot study. Eur Arch Otorrinolaringol 281(5):2637\u20132644. https:\/\/doi.org\/10.1007\/s00405-024-08537-9","journal-title":"Eur Arch Otorrinolaringol"},{"issue":"7","key":"1_CR172","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/qad.0000000000001773","volume":"32","author":"A Weinberg","year":"2018","unstructured":"Weinberg A, Huang S, Moscicki AB, Saah A, Levin MJ (2018) Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. AIDS 32(7):851\u2013860. https:\/\/doi.org\/10.1097\/qad.0000000000001773","journal-title":"AIDS"},{"issue":"3","key":"1_CR173","first-page":"636","volume":"63","author":"MJ Welters","year":"2003","unstructured":"Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH (2003) Frequent display of human papillomavirus type 16 E6-specific memory t-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63(3):636\u2013641","journal-title":"Cancer Res"},{"issue":"1","key":"1_CR174","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2412391","volume":"20","author":"T Wen","year":"2024","unstructured":"Wen T, Xu X, Pan C, Hu S, Zhao H, Zhang X, Qiao Y, Zhao F (2024) The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20-45 years of age. Hum Vaccin Immunother 20(1):2412391. https:\/\/doi.org\/10.1080\/21645515.2024.2412391","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1_CR175","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/s1470-2045(11)70287-x","volume":"13","author":"CM Wheeler","year":"2012","unstructured":"Wheeler CM, Castellsagu\u00e9 X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmer\u00f3n J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M (2012) Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13(1):100\u2013110. https:\/\/doi.org\/10.1016\/s1470-2045(11)70287-x","journal-title":"Lancet Oncol"},{"issue":"10","key":"1_CR176","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/s1473-3099(16)30120-7","volume":"16","author":"CM Wheeler","year":"2016","unstructured":"Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmer\u00f3n J, McNeil S, Stapleton JT, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, Ter Harmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YKT, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WGV, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F (2016) Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis 16(10):1154\u20131168. https:\/\/doi.org\/10.1016\/s1473-3099(16)30120-7","journal-title":"Lancet Infect Dis"},{"issue":"97","key":"1_CR177","first-page":"645","volume":"50","author":"WHO","year":"2022","unstructured":"WHO (2022) Human papillomavirus vaccines: WHO position paper (2022 update). Wkly Epidemiol Rec 50(97):645\u2013672","journal-title":"Wkly Epidemiol Rec"},{"key":"1_CR178","volume-title":"Walrinvax\u00ae","author":"WHO","year":"2023","unstructured":"WHO (2023) Walrinvax\u00ae. Available from: https:\/\/extranet.who.int\/prequal\/vaccines\/p\/walrinvaxr"},{"key":"1_CR179","volume-title":"WHO adds an HPV vaccine for single-dose use","author":"WHO","year":"2024","unstructured":"WHO (2024) WHO adds an HPV vaccine for single-dose use. Available from: https:\/\/www.who.int\/news\/item\/04-10-2024-who-adds-an-hpv-vaccine-for-single-dose-use"},{"key":"1_CR180","volume-title":"Human papillomavirus (HPV) vaccination coverage","author":"WHO","year":"2025","unstructured":"WHO (2025a) Human papillomavirus (HPV) vaccination coverage. https:\/\/immunizationdata.who.int\/pages\/coverage\/hpv.html. Accessed 19 June 2025"},{"key":"1_CR181","volume-title":"Human papillomavirus vaccines (HPV)","author":"WHO","year":"2025","unstructured":"WHO (2025b) Human papillomavirus vaccines (HPV). https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/human-papillomavirus-vaccines-(HPV). Accessed 19 June 2025"},{"key":"1_CR0177","unstructured":"WHO (2025c) Global leaders unite to accelerate cervical cancer elimination efforts. Joint News Release. Bali, Indonesia. https:\/\/www.who.int\/westernpacific\/news\/item\/19-06-2025-global-leaders-unite-to-accelerate-cervical-cancer-elimination-efforts. Accessed 23 Jan 26"},{"key":"1_CR182","doi-asserted-by":"publisher","unstructured":"Williamson AL (2023) Recent developments in human papillomavirus (HPV) vaccinology. Viruses 15(7). https:\/\/doi.org\/10.3390\/v15071440","DOI":"10.3390\/v15071440"},{"issue":"3","key":"1_CR183","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/infdis\/jiab390","volume":"225","author":"RL Winer","year":"2022","unstructured":"Winer RL, Lin J, Querec TD, Unger ER, Stern JE, Rudd JM, Golden MR, Swanson F, Markowitz LE, Meites E (2022) Effectiveness of human papillomavirus (HPV) vaccination against penile HPV infection in men who have sex with men and transgender women. J Infect Dis 225(3):422\u2013430. https:\/\/doi.org\/10.1093\/infdis\/jiab390","journal-title":"J Infect Dis"},{"key":"1_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100196","volume":"13","author":"X Yao","year":"2021","unstructured":"Yao X, Chen W, Zhao C, Wei L, Hu Y, Li M, Lin Z, Lin B, Liu X, Hong Y, Li Q, Pan Q, Zhang X, Li M, Zhao Y, Zhang L, Xu H, Hu F, Zhao J, Huang Y, Sheng W, Zheng Y, Hu S, Su Y, Huang S, Pan H, Zhao F, Qiao Y, Wu T, Zhang J, Xia N (2021) Naturally acquired HPV antibodies against subsequent homotypic infection: a large-scale prospective cohort study. Lancet Reg Health West Pac 13:100196. https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100196","journal-title":"Lancet Reg Health West Pac"},{"issue":"4","key":"1_CR185","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3892\/etm.2017.4150","volume":"13","author":"M Yokomine","year":"2017","unstructured":"Yokomine M, Matsueda S, Kawano K, Sasada T, Fukui A, Yamashita T, Komatsu N, Shichijo S, Tasaki K, Matsukuma K, Itoh K, Kamura T, Ushijima K (2017) Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females. Exp Ther Med 13(4):1500\u20131505. https:\/\/doi.org\/10.3892\/etm.2017.4150","journal-title":"Exp Ther Med"},{"issue":"7","key":"1_CR186","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/21645515.2020.1761202","volume":"16","author":"XJ Yu","year":"2020","unstructured":"Yu XJ, Li J, Lin ZJ, Zhao H, Lin BZ, Qiao YL et al (2020) Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals. Hum Vaccin Immunother 16(7):1630\u20131635","journal-title":"Hum Vaccin Immunother"},{"key":"1_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102759","volume":"95","author":"T Zadeh Mehrizi","year":"2025","unstructured":"Zadeh Mehrizi T, Ataei-Pirkooh A, Eshrati B, Ebrahimi Shahmabadi H (2025) Investigating factors affecting the effectiveness of Gardasil 4, Cervarix, and Gardasil 9 vaccines considering the WHO regions in females: a systematic review. Cancer Epidemiol 95:102759. https:\/\/doi.org\/10.1016\/j.canep.2025.102759","journal-title":"Cancer Epidemiol"},{"issue":"9","key":"1_CR188","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/j.vaccine.2024.02.077","volume":"42","author":"K Zaman","year":"2024","unstructured":"Zaman K, Schuind AE, Adjei S, Antony K, Aponte JJ, Buabeng PB, Qadri F, Kemp TJ, Hossain L, Pinto LA, Sukraw K, Bhat N, Agbenyega T (2024) Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9\u201314 years of age: Interim analysis from a phase 3 clinical trial. Vaccine 42(9):2290\u20132298. https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.077","journal-title":"Vaccine"},{"key":"1_CR189","doi-asserted-by":"publisher","unstructured":"Zeng Y, Moscicki AB, Woo H, Hsu CH, Kemp TJ, Pinto LA, Szabo E, Dimond E, Bauman J, Sahasrabuddhe VV, Chow HS (2023) HPV16\/18 antibody responses after a single dose of nonavalent HPV vaccine. Pediatrics 152(1). https:\/\/doi.org\/10.1542\/peds.2022-060301","DOI":"10.1542\/peds.2022-060301"},{"issue":"5","key":"1_CR190","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1080\/21645515.2015.1016675","volume":"11","author":"X Zhang","year":"2015","unstructured":"Zhang X, Lu X, Shaowei L, Mujin F, Jun Z, Ningshao X, Zhao Q (2015) Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother 11(5):1277\u20131292. https:\/\/doi.org\/10.1080\/21645515.2015.1016675","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02083-w","volume":"10","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Qiu K, Ren J, Zhao Y, Cheng P (2025) Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use. Signal Transduct Target Ther 10(1):44. https:\/\/doi.org\/10.1038\/s41392-024-02083-w","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1_CR192","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1002\/ijc.28896","volume":"135","author":"FH Zhao","year":"2014","unstructured":"Zhao FH, Zhu FC, Chen W, Li J, Hu YM, Hong Y, Zhang YJ, Pan QJ, Zhu JH, Zhang X, Chen Y, Tang H, Zhang H, Durand C, Datta SK, Struyf F, Bi D (2014a) Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Int J Cancer 135(11):2604\u20132611. https:\/\/doi.org\/10.1002\/ijc.28896","journal-title":"Int J Cancer"},{"issue":"3","key":"1_CR193","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4161\/hv.27619","volume":"10","author":"H Zhao","year":"2014","unstructured":"Zhao H, Zhi-Jie L, Shou-Jie H, Juan L, Xiao-Hui L, Meng G, Jun Z, Ning-Shao X, Hui-Rong P, Ting W, Li C-G (2014b) Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Hum Vaccin Immunother 10(3):740\u2013746. https:\/\/doi.org\/10.4161\/hv.27619","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"1_CR194","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2052700","volume":"18","author":"C Zhao","year":"2022","unstructured":"Zhao C, Zhao Y, Li J, Li M, Su Y, Mi X, La Tu SY, Shen D, Ren L, Li Y, Wang L, Wei L (2022) The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age. Hum Vaccin Immunother 18(5):2052700. https:\/\/doi.org\/10.1080\/21645515.2022.2052700","journal-title":"Hum Vaccin Immunother"},{"key":"1_CR195","volume":"62","author":"G-H Zhong","year":"2025","unstructured":"Zhong G-H, Bi Z-F, Chu K, Zhang L, Chen L, Zhu K-X et al (2025) Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial. Lancet Reg Health 62:101671","journal-title":"Lancet Reg Health"},{"key":"1_CR196","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fonc.2019.00682","volume":"9","author":"C Zhou","year":"2019","unstructured":"Zhou C, Tuong ZK, Frazer IH (2019) Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front Oncol 9:682. https:\/\/doi.org\/10.3389\/fonc.2019.00682","journal-title":"Front Oncol"},{"issue":"11","key":"1_CR197","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/s1473-3099(23)00275-x","volume":"23","author":"FC Zhu","year":"2023","unstructured":"Zhu FC, Zhong GH, Huang WJ, Chu K, Zhang L, Bi ZF et al (2023) Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial. Lancet Infect Dis 23(11):1313\u20131322. https:\/\/doi.org\/10.1016\/s1473-3099(23)00275-x","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1_CR198","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/21645515.2017.1407896","volume":"14","author":"M Zurek Munk-Madsen","year":"2018","unstructured":"Zurek Munk-Madsen M, Toft L, Kube T, Richter R, Ostergaard L, S\u00f8gaard OS, Tolstrup M, Kaufmann AM (2018) Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection. Hum Vaccin Immunother 14(4):909\u2013916. https:\/\/doi.org\/10.1080\/21645515.2017.1407896","journal-title":"Hum Vaccin Immunother"}],"container-title":["Current Topics in Microbiology and Immunology","Human Papillomavirus Epidemiology, Immunology and Cervical Cancer Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-17775-9_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:07:10Z","timestamp":1778573230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-17775-9_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032177742","9783032177759"],"references-count":200,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-17775-9_1","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-032-17775-9","asserted-by":"object"}]},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"16 February 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Hannah S. Newton declares that she has no conflict of interest. Daniel B. Zwick declares that he has no conflict of interest. Troy J. Kemp declares that he has no conflict of interest.\u00a0Ligia A. Pinto declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This chapter is a review of previously published work. No animal or human studies were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}